Rafferty Asset Management
AVDL

Rafferty Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Rafferty Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,884
Closed -$235K – 1067
2025
Q4 		$235K Buy
10,884
+158
+1% +$3.07K ﹤0.01% 1054
2025
Q3 		$164K Buy
+10,726
New +$140K ﹤0.01% 1083

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Rafferty Asset Management's AVDL Position: Q1 2026 in Review

Rafferty Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,884 shares — an estimated $235K sold.

Rafferty Asset Management first reported a position in AVDL in Q3 2025 and held it in 2 quarters. The position peaked at $235K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Rafferty Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 10,884 Avadel Pharmaceuticals shares in Q1 2026, an estimated $235K.
  • Rafferty Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Rafferty Asset Management's Avadel Pharmaceuticals position peaked at $235K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.